New study: LIB-01 believed to be the next generation of powerful drugs


Upsala, November 15, 2022. Dicot’s latest study on LIB-01’s mechanism of action, i.e. how the drug affects the body to achieve the desired effect, shows it stands apart from today’s potent drugs today. This means that LIB-01 can be assumed to represent a new generation of powerful drugs.

Dicot is developing a modern potency drug to treat erectile dysfunction and premature ejaculation better than existing drugs. As part of the long-term development work, studies are underway to map LIB-01’s mechanism of action, i.e. how the drug affects underlying processes in the body so that the desired effect to occur.

The results of a recent ex vivo study show that the mechanism of action of LIB-01 differs from today’s powerful drugs such as, for example, Viagra. These are significant results because today’s potent drugs, with their mechanism of action, do not work optimally for all patients of whom approximately 35% do not have sufficient effect and many report adverse side effects. .

“The fact that we can now postulate that the mechanism of LIB-01 differs from current erectile dysfunction drugs is of great significance, and an indication that LIB-01 could represent a new generation of erectile dysfunction drugs” , comments the professor Francois Giulianourologist specializing in sexual medicine and founder of Pelvipharm.

“With a different mechanism of action than current drugs, we have great potential to show that LIB-01 can treat sexual dysfunctions better than current treatments,” says Elin TrampeCEO of Dicot.

For more information, please contact:

Elin TrampeCEO
Tel: +46 739 80 14 08
[email protected]

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a powerful agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with a significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at 50 billion Swedish crowns. Research and development is conducted under its own auspices up to phase 2 studies. Thereafter, Dicot’s intention is to form strategic alliances, or alternatively make a commercial sale, with larger established pharmaceutical companies. to be able to introduce LIB-01 to the global market.

Dicot is listed on Stock market and has approximately 3,300 shareholders. For more information, visit–publ-/r/new-study–lib-01-assumed-to-be-the-next-generation-of-potency-drugs,c3667393

(c) Decision 2022. All rights reserved., sources Press Releases – English


Comments are closed.